Impact of Metformin Use on Liver Function Tests in Diabetic Patients With Suspected Non-Alcoholic Fatty Liver Disease (NAFLD): A Cross-Sectional Analysis
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent among patients with type 2 diabetes mellitus (T2DM) and is often associated with elevated liver enzymes. Objective: To assess the impact of metformin use on liver function tests in diabetic patients with clinically suspected NAFLD. Methods: This was a cross-sectional analytical study conducted at Jinnah Hospital, Lahore, Pakistan, from July 2024 to December 2024. A total of 185 adult patients were enrolled in the study. Non-probability consecutive sampling was used to recruit participants who met the inclusion criteria. Demographic data, including age, gender, body mass index (BMI), and duration of diabetes, were recorded. Clinical records were reviewed to document metformin use (yes/no), dosage, and duration. Results: Out of 185 patients, 115 (62.2%) were metformin users and 70 (37.8%) were non-users. Metformin users had significantly lower mean alanine aminotransferase (ALT) (41.3 ± 14.6 IU/L vs. 54.7 ± 18.2 IU/L; p < 0.001) and aspartate aminotransferase (AST) levels (35.2 ± 12.4 IU/L vs. 44.6 ± 15.7 IU/L; p = 0.002) compared to non-users. No significant differences were observed in alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) levels. Elevated ALT and AST were significantly less frequent in metformin users (p < 0.01). A weak inverse correlation was observed between metformin dose and ALT levels (r = -0.19, p = 0.043). Conclusion: It is concluded that metformin use is associated…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.